If you have ulcerative colitis and your gastroenterologist has prescribed Omvoh, the practical question is whether UnitedHealthcare will pay for it and what you have to do first. Omvoh, the brand name for mirikizumab-mrkz, is a humanized monoclonal antibody that selectively binds the p19 subunit of interleukin-23 and is FDA-approved for moderately to severely active ulcerative colitis in adults. UnitedHealthcare does cover Omvoh for ulcerative colitis, but coverage is conditional. It runs through a prior authorization process, it typically expects you to have tried other treatments first, and the benefit is split across two parts of your plan. Understanding those mechanics ahead of time is the difference between a smooth approval and a months-long back-and-forth.
How UnitedHealthcare Splits the Omvoh Benefit
Omvoh is given in two phases, and that split matters for how UnitedHealthcare processes the claim. The FDA label calls for three intravenous induction doses of 300 mg at weeks 0, 4, and 8, followed by 200 mg subcutaneously at week 12 and every four weeks after that. The intravenous infusions are administered in a clinic or infusion center, so they usually fall under your medical benefit. According to UnitedHealthcare's own medical benefit drug policy for Omvoh, the self-administered subcutaneous maintenance injection is generally obtained under the pharmacy benefit, which UnitedHealthcare runs through OptumRx, unless your specific plan document says otherwise. Knowing which benefit applies tells you where to direct questions and which deductible and coinsurance you are working against.
What UnitedHealthcare Typically Requires Before Approval
Omvoh requires prior authorization, and the criteria are specific. Reading UnitedHealthcare's published Omvoh coverage policy, the plan generally expects a documented diagnosis of moderately to severely active ulcerative colitis and that the prescription comes from or is made in consultation with a gastroenterologist. The policy also typically asks for one of two history elements before it will deem Omvoh medically necessary.
A prior or concurrent inadequate response to oral corticosteroids and/or immunosuppressants such as azathioprine or 6-mercaptopurine
Previous treatment with another systemic targeted immunomodulator approved for ulcerative colitis, for example adalimumab, vedolizumab, or upadacitinib
The policy also states that Omvoh will not be approved if you are taking it together with another targeted immunomodulator for the same condition. Plan documents change, so confirm the current version that applies to you.
Why Step Therapy Applies to Omvoh
The requirement to have tried other agents first is a form of step therapy, and it reflects how ulcerative colitis is treated in practice. The American Gastroenterological Association's living guideline on moderate-to-severe ulcerative colitis lists mirikizumab among the advanced therapies recommended over no treatment, alongside agents like infliximab, vedolizumab, and upadacitinib. Because several effective options exist, insurers often direct members toward preferred or lower-cost agents before approving a newer one. The clinical evidence behind Omvoh is solid. In the phase 3 LUCENT trials published in the New England Journal of Medicine, clinical remission at week 12 reached 24.2% on mirikizumab versus 13.3% on placebo, and 49.9% versus 25.1% at week 40 of maintenance. That evidence supports approval once you meet the prior-treatment criteria.
How to Verify Your Own Plan and Formulary
UnitedHealthcare plans vary widely, so the policy language above is a starting point, not a guarantee for your specific situation. Formulary placement, tier, and out-of-pocket cost depend on your individual benefit design. To confirm your details, pull your plan's formulary or prescription drug list and your summary of benefits, both available through your member portal, and check how Omvoh is listed and whether it routes through OptumRx or Optum Specialty Pharmacy. You can also call the member services number on your card to ask whether Omvoh requires prior authorization under your plan and what documentation is needed. Eli Lilly's Omvoh savings and support program offers insurance navigation help and, for eligible commercially insured patients, a copay card, though government beneficiaries such as those on Medicare or Medicaid are excluded.
Building the Medical-Necessity Case and Appealing a Denial
Because approval turns on documentation, the prior authorization succeeds or fails on what your gastroenterologist submits. The strongest packets include the confirmed diagnosis with disease severity, a clear record of which prior treatments you tried, the dates, and why each was stopped, whether for inadequate response, loss of response, or intolerance. That history is exactly what UnitedHealthcare's Omvoh policy keys on. If the initial request is denied, you have the right to appeal. A first-level appeal usually involves your physician submitting a letter of medical necessity that maps your history directly to the plan's stated criteria, and many plans offer a peer-to-peer review where your gastroenterologist speaks with the plan's reviewer. Keeping a complete, dated record of your symptoms and prior therapies before you apply makes both the initial request and any appeal far more straightforward.
The Bottom Line on UnitedHealthcare and Omvoh
UnitedHealthcare covers Omvoh for ulcerative colitis, but the path runs through prior authorization, typical step-therapy expectations, and a benefit split between medical infusions and pharmacy-managed maintenance injections. The plan generally wants to see a gastroenterologist-confirmed diagnosis of moderately to severely active disease and either an inadequate response to steroids or immunosuppressants or prior use of another approved advanced therapy. None of these requirements should be treated as fixed dollar amounts or guaranteed tiers, because your specific plan controls the final terms. The most reliable approach is to read your own formulary, confirm prior authorization requirements directly with UnitedHealthcare or OptumRx, and assemble a thorough treatment history with your gastroenterologist so the medical-necessity case is ready before the first request goes in.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.